Article

B + L submits NDA for new formulation of bromfenac

Bausch + Lomb (B + L) has submitted a new drug application (NDA) to the FDA, seeking approval for a bromfenac ophthalmic solution (Prolensa) for the treatment of ocular inflammation and pain following cataract surgery.

Madison, NJ-Bausch + Lomb (B + L) has submitted a new drug application (NDA) to the FDA, seeking approval for a bromfenac ophthalmic solution (Prolensa) for the treatment of ocular inflammation and pain following cataract surgery.

The once-daily topical nonsteroidal anti-inflammatory drug (NSAID), developed by recently acquired ISTA Pharmaceuticals, incorporates a lower concentration of bromfenac than the currently available once-daily formulation (Bromday, which has a 0.09% concentration) in a new formulation.

“The new, optimized formulation used for [the solution] allows for a lower concentration of bromfenac while maintaining the convenience of once-daily use currently prescribed with [the existing formulation],” said Calvin Roberts, MD, executive vice president, chief medical officer, B + L.

The U.S. Patent and Trademark Office recently issued a patent, expiring in 2025, for the new product’s formulation and method of use to the licensor, Senju Pharmaceutical Co. Ltd.

“The [NDA] filing is an important step toward bringing safe, effective, and meaningful medical advances to medical professionals and their patients,” said Marvin Garrett, B + L’s vice president of U.S. regulatory affairs, quality assurance, and compliance. “It’s also a timely example of the progress we continue to make on critical [research and development] programs as we work to bring together the best of ISTA Pharmaceuticals and B + L.”

In May 2002, ISTA acquired U.S. ophthalmic rights to bromfenac under a license from Senju Pharmaceuticals Co. Ltd. From 2005 to 2011, ISTA marketed a twice-daily solution of bromfenac 0.09% (Xibrom) in the United States for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. In October 2010, ISTA received FDA approval for the currently available once-daily formulation; the company discontinued shipments of the twice-daily formulation in February 2011. In June 2012, B + L acquired ISTA.

The current bromfenac solution is the only once-daily treatment option in the U.S. ophthalmic NSAID market.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.